Fresenius Medical Care : The next negative surprise – guidance cut on labour constraints and inflation
>Preliminary Q2 results - Q2 revenues of € 4,757m (+10.1% y-o-y) were 1% ahead of our forecast, but we acknowledge that the apparently strong performance came only on the back of a forex tailwind of 900bp. The company reported only a flat organic performance (1% external growth contribution). Health Care Services had only a flat organic development as the North American region were harshly affected by labour shortage, declines in co-insurance, which resulted in an org...RegistrarFresenius Medical Care is a kidney dialysis company, operating in both the field of dialysis services and the field of dialysis products for the treatment of end-stage renal disease (ESRD). Co.'s dialysis business is vertically integrated, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a range of products. In addition, Co. sells dialysis products to other dialysis service providers. In the U.S.A., Co. also provides inpatient dialysis services and other services under contract to hospitals. Co. provides patient services, including renal pharmaceutical products and in the U.S.A., laboratory services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.